Within-trial cost-effectiveness of lifestyle intervention using a 3-tier shared care approach for pregnancy outcomes in Chinese women with gestational diabetes.
Weiqin LiCuiping ZhangJunhong LengPing ShaoHuiguang TianFuxia ZhangLing DongZhijie YuJuliana C N ChanGang HuPing ZhangXilin YangPublished in: PloS one (2020)
This study assessed within-trial cost-effectiveness of a shared care program (SC, n = 339) for pregnancy outcomes compared to usual care (UC, n = 361), as implemented in a randomized trial of Chinese women with gestational diabetes (GDM). SC consisted of an individualized dietary advice and physical activity counseling program. The UC was a one-time group education program. The effectiveness was measured by number needed to treat (NNT) to prevent one macrosomia/large for gestational age (LGA) infant. The cost-effectiveness was measured by incremental cost-effectiveness ratio in terms of cost (2012 Chinese Yuan/US dollar) per case of macrosomia and LGA prevented. The study took both a health care system and a societal perspective. This study found that the NNT was 16/14 for macrosomia/LGA. The incremental cost for treating a pregnant woman was ¥1,877 ($298) from a health care system perspective and ¥2,056 ($327) from a societal perspective. The cost of preventing a case of macrosomia/LGA from the two corresponding perspectives were ¥30,032/¥26,278 ($4,775/$4,178) and ¥32,896/¥28,784 ($5,230/$4,577), respectively. Considering the potential severe adverse health and economic consequences of a macrosomia/LGA infant, our findings suggest that implementing this lifestyle intervention for women with GDM is an efficient use of health care resources.
Keyphrases
- healthcare
- pregnancy outcomes
- quality improvement
- physical activity
- randomized controlled trial
- pregnant women
- palliative care
- gestational age
- metabolic syndrome
- study protocol
- cardiovascular disease
- type diabetes
- mental health
- public health
- pain management
- preterm birth
- body mass index
- affordable care act
- phase ii
- smoking cessation
- human immunodeficiency virus
- early onset
- hepatitis c virus
- phase iii